New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
10:43 EDTSNSS, LCI, CSTM, TRP, AFL, EGHT, MOBI, LITBHigh option volume stocks
High option volume stocks: LITB AFL LCI MOBI TRP TASR AMRN SNSS EGHT CSTM
News For LITB;AFL;LCI;MOBI;TRP;SNSS;EGHT;CSTM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
13:21 EDTLCILannett receives FDA approval for Dorzolamide HCL with Timolol
Lannett announced that it has received approval from the U.S. FDA of its Abbreviated New Drug Application for Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution, 2%/0.5%, the therapeutic equivalent to the reference listed drug, Cosopt Ophthalmic Solution, 2%/0.5%, of Oak Pharmaceuticals, Inc.. According to IMS, for the year ended October 2014 total sales of Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution, 2%/0.5%, at Average Wholesale Price were approximately $123M.
09:09 EDTEGHT8x8, Inc. issued new conferencing and meeting patent by USPTO
Subscribe for More Information
December 16, 2014
06:07 EDTLITBLightInTheBox extends share repurchase program for additional twelve months
Subscribe for More Information
December 15, 2014
10:00 EDTSNSSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:27 EDTSNSSSunesis upgraded at Roth Capital
Subscribe for More Information
06:06 EDTSNSSSunesis upgraded to Buy from Neutral at Roth Capital
Subscribe for More Information
December 10, 2014
10:00 EDTSNSSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:23 EDTSNSSOn The Fly: Pre-market Movers
Subscribe for More Information
09:03 EDTAFLAflac becomes official insurance partner of the Grammy's
Subscribe for More Information
06:40 EDTSNSSSunesis upgraded to Buy from Hold at Cantor
Subscribe for More Information
December 8, 2014
17:34 EDTLCILannett served with subpoena in federal probe related to generic industry
Subscribe for More Information
13:34 EDTSNSSSunesis announces positive results from ongoing trial of Vosaroxin
Subscribe for More Information
12:40 EDTSNSSOn The Fly: Midday Wrap
Subscribe for More Information
11:30 EDTLCILeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
09:29 EDTSNSSSunesis risk/reward attractive, says RBC Capital
RBC Capital believes that the EU could approve Sunesis' vosaroxin drug. The firm says that an EU approval would lift the stock by about 35%, and ir keeps a $3 price target and Sector Perform rating on the shares.
05:51 EDTSNSSSunesis to host conference call
Conference call to discuss results from the Phase 3 VALOR trial of vosaroxin and cytarabine will be held on December 9 at 1:30 pm. Webcast Link
December 7, 2014
16:42 EDTSNSSSunesis announces presentation of Phase 3 VALOR trial results
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use